Cannabinoid review finds no dementia symptom benefit, more somnolence
Efficacy and safety of cannabinoid-based interventions for behavioral and cognitive symptoms in dementia: systematic review and meta-analysis.
AI Summary
This systematic review and meta-analysis examined whether cannabinoid-based therapies improve behavioral and cognitive symptoms in people with Alzheimer’s disease or dementia. It included 9 randomized controlled trials involving 334 participants. Compared with placebo or control treatment, cannabinoids did not improve agitation measured by the Cohen-Mansfield Agitation Inventory (CMAI), overall neuropsychiatric symptoms, agitation on the Neuropsychiatric Inventory-Nursing Home version (NPI-NH), or cognition measured by the Mini-Mental State Examination (MMSE). Bayesian analyses also produced estimates close to zero, supporting no meaningful effect in these outcomes.
Overall adverse events were similar to placebo, but somnolence—excessive sleepiness—was more frequent with cannabinoids (risk ratio 2.03, 95% CI 1.29–3.20). The evidence was judged moderate for behavioral outcomes and low for cognition, with substantial variation between trials, particularly for agitation and cognitive measures. This abstract-based summary cannot establish whether particular cannabinoid formulations, doses, treatment durations, or patient subgroups might differ; it also does not provide enough information to assess long-term effects.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Brain blood-flow reductions in acute anorexia follow a cortical hierarchy
CBD showed limited adaptive-functioning differences versus placebo in boys…
Resilience linked to depression outcomes and THC positivity
Explore More Research
Stay informed about the latest cannabis science.